Edition:
India

Bio Rad Laboratories Inc (BIO.N)

BIO.N on New York Stock Exchange

477.66USD
10 Jul 2020
Change (% chg)

$-0.38 (-0.08%)
Prev Close
$478.04
Open
$479.97
Day's High
$479.97
Day's Low
$474.09
Volume
59,099
Avg. Vol
89,856
52-wk High
$496.96
52-wk Low
$304.25

Latest Key Developments (Source: Significant Developments)

The International Trade Commission Issues Final Decision Affirming 10X Genomics Infringement Of Three Of Bio-Rad's Patents
Monday, 23 Dec 2019 

Dec 23 (Reuters) - Bio-Rad Laboratories Inc ::THE INTERNATIONAL TRADE COMMISSION ISSUES FINAL DECISION AFFIRMING 10X GENOMICS INFRINGEMENT OF THREE OF BIO-RAD’S PATENTS.BIO RAD LABORATORIES INC - ITC ALSO ISSUED A LIMITED EXCLUSION ORDER AND CEASE AND DESIST ORDER AGAINST 10X GENOMICS.BIO RAD LABORATORIES-ITC DECISION DOESN'T AFFECT CO'S ONGOING LAWSUITS IN DELAWARE AND MASSACHUSETTS THAT ACCUSE 10X INFRINGING OTHER BIO-RAD PATENTS.  Full Article

(OFFICIAL)-BRIEF-Bio-Rad Posts Q2 EPS Of $19.86 (Aug. 1)
Wednesday, 28 Aug 2019 

Corrects Q2 non-GAAP EPS in second bullet to $1.49, from $1.57, as the company's prior press release contained a $3.37 million error related to legal matters:BIO-RAD REPORTS SECOND-QUARTER 2019 FINANCIAL RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $1.49.Q2 EARNINGS PER SHARE $19.86.Q2 SALES $572.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $566.2 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $1.34 -- REFINITIV IBES DATA.FOR FY 2019, COMPANY CONTINUES TO ANTICIPATE CURRENCY-NEUTRAL REVENUE GROWTH OF APPROXIMATELY 4.0 TO 4.5%.  Full Article

Bio Rad Labs Says Entered Credit Agreement Dated April 15 Replacing Previous Credit Agreement Dated June 20, 2014
Wednesday, 17 Apr 2019 

April 16 (Reuters) - Bio Rad Laboratories Inc ::BIO RAD LABORATORIES SAYS ENTERED CREDIT AGREEMENT DATED APRIL 15 REPLACING PREVIOUS CREDIT AGREEMENT DATED JUNE 20, 2014 - SEC FILING.BIO RAD - UNDER TERMS, BORROWINGS PERMITTED UP TO MAXIMUM AMOUNT OF $200 MILLION ON REVOLVING BASIS, INCLUDING UP TO $25 MILLION OF LETTERS OF CREDIT.BIO RAD - UNDER CERTAIN CONDITIONS, BORROWINGS MAY BE INCREASED UP TO ADDITIONAL $400 MILLION.BIO RAD LABORATORIES INC - REVOLVING CREDIT AGREEMENT MATURES ON APRIL 15, 2024.  Full Article

Bio Rad Names Ilan Daskal Executive Vice President And CFO
Wednesday, 3 Apr 2019 

April 2 (Reuters) - Bio Rad Laboratories Inc ::BIO-RAD NAMES ILAN DASKAL EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER.BIO RAD LABORATORIES INC - ILAN DASKAL AS EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE APRIL 6, 2019.  Full Article

Bio Rad Laboratories Files For Non-Timely 10K - SEC Filing
Monday, 4 Mar 2019 

March 4 (Reuters) - Bio Rad Laboratories Inc ::BIO RAD LABORATORIES INC FILES FOR NON-TIMELY 10K - SEC FILING.  Full Article

Bio-Rad Reports Fourth-Quarter And Full-Year 2018 Financial Results
Friday, 1 Mar 2019 

Feb 28 (Reuters) - Bio Rad Laboratories Inc ::BIO-RAD REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS.Q4 NON-GAAP EARNINGS PER SHARE $2.13.Q4 LOSS PER SHARE $27.88.Q4 SALES $617.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $609 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $1.70 -- REFINITIV IBES DATA.BIO RAD LABORATORIES - FOR FULL YEAR 2019, ANTICIPATES CURRENCY-NEUTRAL REVENUE GROWTH OF APPROXIMATELY 4.0 TO 4.5 PERCENT.FOR 2019, CO ANTICIPATES IMPROVED PROFITABILITY WITH ESTIMATED NON-GAAP OPERATING MARGIN OF 12.5 TO 13 PERCENT.  Full Article

Bio-Rad Q3 Non-Gaap Earnings Per Share $0.91
Friday, 2 Nov 2018 

Nov 1 (Reuters) - Bio Rad Laboratories Inc ::BIO-RAD REPORTS THIRD-QUARTER 2018 FINANCIAL RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $0.91.Q3 EARNINGS PER SHARE $8.89.Q3 SALES $545.1 MILLION VERSUS I/B/E/S VIEW $538.7 MILLION.Q3 EARNINGS PER SHARE VIEW $1.15 -- THOMSON REUTERS I/B/E/S.FOR FULL YEAR 2018, COMPANY IS REITERATING PREVIOUS CURRENCY-NEUTRAL GROWTH REVENUE OUTLOOK OF 4.0 TO 4.5 PERCENT.  Full Article

BRIEF-Bio Rad Laboratories Estimates Q2 Currency-Neutral Sales To Decline By 5% To 10%

* BIO RAD LABORATORIES SAYS IT EXPECTS Q2 2020 YEAR-OVER-YEAR CURRENCY NEUTRAL SALES MAY DECLINE BY 5 TO 10 PERCENT - SEC FILING Source text: (https://bit.ly/3glQfJ0) Further company coverage: